BCL2 and acute lymphoblastic leukemia: Taking advantage of ABT-199 (also known as Venetoclax) [22], an available drug designed to target specifically the BH3-domain of BCL2, we confirmed that the drug resistance of Zeb2Tg ETP-ALL to LSD1i is active essentially through BCL2 protein that is regulated by IL7/IL7R through JAK/STAT pathway (Fig. 3E).